Ensysce Biosciences Valuation
| ENSCWDelisted Stock | USD 0.01 0.0008 8.16% |
Ensysce Biosciences seems to be overvalued based on Macroaxis valuation methodology. Our model computes the value of Ensysce Biosciences from reviewing the firm fundamentals such as Net Asset of 16.42 M, total debt of 4.44 M, and Z Score of -3.3 as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Ensysce Biosciences' price fluctuation is very steady at this time. Calculation of the real value of Ensysce Biosciences is based on 3 months time horizon. Increasing Ensysce Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Ensysce pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Ensysce Biosciences. Since Ensysce Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ensysce Pink Sheet. However, Ensysce Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.009 | Real 0.00855 | Hype 0.01 | Naive 0.0102 |
The intrinsic value of Ensysce Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Ensysce Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Ensysce Biosciences helps investors to forecast how Ensysce pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ensysce Biosciences more accurately as focusing exclusively on Ensysce Biosciences' fundamentals will not take into account other important factors: Ensysce Biosciences Total Value Analysis
Ensysce Biosciences is currently forecasted to have takeover price of 0 with market capitalization of 0, debt of 4.44 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Ensysce Biosciences fundamentals before making investing decisions based on enterprise value of the companyEnsysce Biosciences Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The latest return on assets of Ensysce indicates not a very effective usage of assets in November.Ensysce Biosciences Profitability Analysis
Net Loss for the year was (29.15 M) with profit before overhead, payroll, taxes, and interest of 0.About Ensysce Biosciences Valuation
Our relative valuation model uses a comparative analysis of Ensysce Biosciences. We calculate exposure to Ensysce Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Ensysce Biosciences's related companies.Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. Ensysce Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Ensysce Biosciences' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Ensysce Biosciences' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Ensysce Biosciences' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Ensysce Biosciences' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Ensysce Biosciences' revenue streams: Identify Ensysce Biosciences' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Ensysce Biosciences' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Ensysce Biosciences' growth potential: Evaluate Ensysce Biosciences' management, business model, and growth potential.
- Determine Ensysce Biosciences' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Ensysce Biosciences' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Ensysce Biosciences Growth Indicators
Investing in growth stocks can be very risky. If the company such as Ensysce Biosciences does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.2 M | |
| Retained Earnings | -85.8 M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Ensysce Pink Sheet
If you are still planning to invest in Ensysce Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ensysce Biosciences' history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |